T1	Participants 450 750	624 (94%) and 462 (69%), respectively, of 667 postmenopausal women with hormone responsive early breast cancer treated by surgery followed by adjuvant treatment with tamoxifen +/- octreotide in a randomized trial (NCIC CTG MA.14; National Cancer Institute of Canada Clinical Trials Group Mammary.14).
T2	Participants 786 853	2,540 samples; 688 at baseline and 1,852 collected during follow-up
